[Biological and physical approach to the improvement of radiotherapy].
A double blind trial of misonidazole (MISO) was undertaken. A total of 147 patients were enrolled. They were randomly allocated into two groups receiving either MISO or placebo. They were irradiated with 2 Gy 5 times a week to a total dose of about 60 Gy. 0.5g/m2 of MISO was given orally 4 hours before each irradiation. The effect of the treatment was evaluated as a decrease in the volume of the tumors. No radiosensitizing effect of the drug was observed. Twenty-nine tumors considered to be radioresistant were treated by RF hyperthermia combined with radiation. 48% of the tumors developed complete regression. No definite relationship between heat sensitivity of the tumors and their histological types was observed.
D000818:Animals; D002470:Cell Survival / Q000528:radiation effects; D006358:Hot Temperature / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000008:administration & dosage*; D009593:Nitroimidazoles / Q000008:administration & dosage*; D011878:Radiotherapy / Q000592:standards
D009593:Nitroimidazoles; D008920:Misonidazole